Ardelyx (Nasdaq: ARDX) announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE